Systemic inflammatory syndrome in children during COVID-19 pandemic in Ceará state, northeastern Brazil: an observational study

In this study, we report the occurrence of multisystemic inflammatory syndrome among 64 children (2 deaths) with recent severe acute respiratory syndrome-related coronavirus 2 (SARS-COV-2) infections in the northeast region of Brazil. The major clinical symptoms and signs reported were exanthema (60...

Full description

Saved in:
Bibliographic Details
Published inRevista da Sociedade Brasileira de Medicina Tropical Vol. 54; p. e0383
Main Authors Farias, Luís Arthur Brasil Gadelha, Almeida, Magda Moura de, Linhares, Pâmela Maria Costa, Brito Alves, Bruno Cavalcante Fales de, Duarte Filho, Roberto Jorge Colares, Leite, Roberio Dias, Safadi, Marco Aurelio Palazzi, Cavalcanti, Luciano Pamplona de Góes
Format Journal Article
LanguageEnglish
Published Sociedade Brasileira de Medicina Tropical - SBMT 01.01.2021
Sociedade Brasileira de Medicina Tropical (SBMT)
Subjects
Children
COVID-19
Multisystem inflammatory syndrome in children
SARS-CoV-2
Short Communication
TROPICAL MEDICINE
COVID-19
SARS-CoV-2
Multisystem inflammatory syndrome in children
Children
Online AccessGet full text

Cover

More Information
Summary:In this study, we report the occurrence of multisystemic inflammatory syndrome among 64 children (2 deaths) with recent severe acute respiratory syndrome-related coronavirus 2 (SARS-COV-2) infections in the northeast region of Brazil. The major clinical symptoms and signs reported were exanthema (60.9%), abdominal pain (56.3%), nausea and vomiting (46.9%), diarrhea (37.5%), and dyspnea (37.5%). Laboratory findings revealed that the levels of C-reactive protein (75.0%), hemoglobin (51.6%), D-dimer (48.4%), lymphocytes (43.8%), LDH (45.3%), AST (42.2%), ALT (51.6%), and ferritin (48.4%) were above the reference values for a given age and gender. The clinical findings were similar to those observed in Kawasaki disease, although it represents a separate entity, emphasizing the need for proactive surveillance and early treatment.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
Conflict of Interest: MAPS received consultancy fees and research grants from Pfizer, Astra Zeneca and Janssen. The other authors declare that there is no conflict of interest.
Authors’ contribution: I certify that all the authors have participated sufficiently in the conception and design of this work and the analysis of the data (where applicable and within each area of expertise), or the writing of the manuscript, and to take public responsibility for it. I warrant that this work is original and scientifically accurate, that it is not defamatory, does not invade any right of privacy, and does not infringe on any proprietary right or copyright. We believe the manuscript represents valid work. Description of each author's role in the research process and in preparing the manuscript: LABGF, PMCL, MAPS and LPGC responsible for drafting the proposal, review of literature and writing the article; LABGF, MMA, PMCL, BF, RJCDF, RDL, MAPS and LPGC drafting the paper or substantially revising it and was responsible for overall direction conception and design of the study.
ISSN:0037-8682
1678-9849
1678-9849
DOI:10.1590/0037-8682-0383-2021